- I-Mab at Jefferies London Healthcare Conference TranscriptNov 14, 2023
- Half Year 2023 I-Mab Earnings Call TranscriptAug 17, 2023$2.3 (-2.95%)Earnings
- Full Year 2022 I-Mab Earnings Call TranscriptMar 31, 2023$3.46 (-1.70%)Earnings
- I-Mab Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab Call TranscriptSep 12, 2022
- Half Year 2022 I-Mab Earnings Call TranscriptAug 30, 2022$5.98 (+2.57%)Earnings
- I-Mab R&D Day TranscriptJul 20, 2022
- I-Mab TJD5 Phase 2 Clinical Trial Data Update Call TranscriptMay 27, 2022
- Full Year 2021 I-Mab Earnings Call TranscriptMar 29, 2022$19.39 (+15.07%)Earnings
- I-Mab at JPMorgan Healthcare Conference (Virtual) TranscriptJan 11, 2022
- I-Mab Corporate Call TranscriptDec 21, 2021
- I-Mab Most Recent Clinical Data Update Conference Call -- English Session TranscriptDec 14, 2021
- I-Mab and Jumpcan To Announce its Strategic Commercial Partnership on Eftansomatropin Alfa - Special Call TranscriptNov 10, 2021
- Half Year 2021 I-Mab Earnings & Corporate Progress Update Conference Call TranscriptAug 31, 2021
- I-Mab to Discuss Phase 1 Data on Highly Differentiated CD73 Antibody Uliledlimab at ASCO 2021 Call TranscriptJun 07, 2021
- I-Mab at Jefferies Healthcare Conference (Virtual) TranscriptJun 01, 2021
- I-Mab Corporate Analyst Meeting TranscriptApr 26, 2021
- Full Year 2020 I-Mab Earnings Call TranscriptMar 29, 2021$44.38 (-4.80%)Earnings
- IMAB Lemzoparlimab Phase 1 Clinical Trial Data Update Conference Call TranscriptNov 13, 2020
- I-Mab SITC Data Conference Call TranscriptNov 09, 2020
- I-Mab Company Update Conference Call TranscriptSep 04, 2020
- Half Year 2020 I-Mab Earnings Call TranscriptAug 31, 2020$39.44 (+27.23%)Earnings
- I-Mab Update Conference Call TranscriptMay 28, 2020
- I-Mab at Bank of America Merrill Lynch Healthcare Conference (Virtual) TranscriptMay 14, 2020
- Full Year 2019 I-Mab Earnings Call TranscriptMar 31, 2020$13 (+4.00%)Earnings
I-Mab Update Conference Call Transcript
Thank you, operator, and thank you, everyone, for joining us today. Last night, after market close, we issued a press release announcing that we have successfully completed part 1 of our randomized double-blind clinical study of TJM2, our proprietary GM-CSF antibody in patients with cytokine release syndrome associated with severe COVID-19. The press release can be accessed on the investors portion of our website at http://i-mabbiopharma.com. Joining me today on the call from I-Mab's senior management team are Dr. Jingwu Zang, our Founder, Honorary Chairman and Director; and Dr. Joan Shen, our Chief Executive Officer and Director; and I am Jielun Zhu, the CFO of the company.
Dr. Joan will provide background of the TJM2 clinical program, discuss the scientific rationale of inhibiting GM-CSF in severe COVID-19 patients and give an overview of the current study we're conducting.
Dr. Shen will then share more details of the clinical trial design and the status, including preliminary findings from part 1 of the study, and we'll discuss our plan to move
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)